Premium
Durable response after just one cycle of belotecan‐based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma
Author(s) -
Lee Guk Jin,
Min Ji Won,
Seo Min Wu,
Lee Mi Yeong,
Jin Jong Youl
Publication year - 2014
Publication title -
journal of obstetrics and gynaecology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 1341-8076
DOI - 10.1111/jog.12161
Subject(s) - medicine , serous fluid , chemotherapy , carcinoma , oncology , combination chemotherapy , surgery , sepsis
The efficacy of second‐line chemotherapy for relapsed primary peritoneal serous carcinoma has been numerously reported, but reports on durable response after second‐line therapy have been rare. We report the case of a 66‐year‐old woman with relapsed primary peritoneal serous carcinoma who showed durable response after just one cycle of second‐line belotecan‐based therapy. The response might be a complete pathologic remission. Considering the fact that our patient suffered from neutropenic sepsis during her treatment, we concluded that belotecan‐based chemotherapy could be a good option for second‐line chemotherapy in some selected patients, so patient selection should be carefully performed due to the toxicity of belotecan.